Article info
Editorial
Niacin—a case study for the role of event-driven versus surrogate endpoint trials
- Correspondence to Dr Michael J Blaha, Department of Medicine/Cardiology, The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Carnegie 565A, JHH, 600 N. Wolfe St., Baltimore, MD 21287, USA; mblaha1{at}jhmi.edu
Citation
Niacin—a case study for the role of event-driven versus surrogate endpoint trials
Publication history
- First published September 16, 2013.
Online issue publication
October 16, 2013
Article Versions
- Previous version (16 September 2013).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions